Kenneth B. Gordon
ORCID:0000-0002-9347-0292
发表论文 334 篇 · 总被引 27113 次 · h-index 74
代表论文
- Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial (2023 · The Lancet · 被引 114)
- Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review (2023 · Dermatology and Therapy · 被引 49)
- Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials ( POETYK PSO ‐1 and PSO ‐2) (2024 · Journal of the European Academy of Dermatology and Venereology · 被引 46)
- Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials (2023 · British Journal of Dermatology · 被引 33)
- Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials (2024 · Dermatology and Therapy · 被引 17)
- Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial (2025 · Journal of the American Academy of Dermatology · 被引 16)